GSK launches shingles vaccine, Shingrix in India
GlaxoSmithKline Pharmaceuticals (GSK) has launched Shingrix (zoster vaccine recombinant, adjuvanted) in India, for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above. Shingrix is a non-live, recombinant subunit vaccine to be given intramuscularly in two doses. Shingles are caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. A seroprevalence study in Indian subjects showed that by the age of 40 years more than 90 per cent had this virus in their body and were vulnerable to shingles. Shingles cause a painful rash. In all cases, the rash disappears, but in a large number of cases, the pain persists for months or years. This pain is known as post-herpetic neuralgia (PHN). Bhushan Akshikar, MD, GSK says,
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
